PRESIDENT & CEO, OUTLOOK THERAPEUTICS
                                    United States Life Sciences 2022
                                    "If our ophthalmic bevacizumab is approved, we will potentially enhance the standard of care for patients with disorders like wet AMD, diabetic macular edema, and branch retinal vein occlusion by removing concerns related to off-label repackaged IV product."